Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 942,059
  • Shares Outstanding, K 169,435
  • Annual Sales, $ 138,100 K
  • Annual Income, $ 31,870 K
  • EBIT $ 23 M
  • EBITDA $ 20 M
  • 60-Month Beta 2.44
  • Price/Sales 5.64
  • Price/Cash Flow 15.28
  • Price/Book 8.49

Options Overview Details

View History
  • Implied Volatility 253.00% (+17.93%)
  • Historical Volatility 95.00%
  • IV Percentile 84%
  • IV Rank 35.65%
  • IV High 550.81% on 03/26/25
  • IV Low 88.02% on 12/22/25
  • Expected Move (DTE 8) 0.89 (16.44%)
  • Put/Call Vol Ratio 0.72
  • Today's Volume 342
  • Volume Avg (30-Day) 3,020
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 52,774
  • Open Int (30-Day) 38,501
  • Expected Range 4.54 to 6.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 5
  • High Estimate -0.03
  • Low Estimate -0.10
  • Prior Year 0.22
  • Growth Rate Est. (year over year) -136.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.09 +32.76%
on 01/13/26
6.35 -14.49%
on 02/04/26
+1.09 (+25.12%)
since 01/12/26
3-Month
3.42 +58.77%
on 11/18/25
6.35 -14.49%
on 02/04/26
+1.20 (+28.37%)
since 11/12/25
52-Week
0.40 +1,257.50%
on 04/07/25
6.35 -14.49%
on 02/04/26
+4.64 (+583.45%)
since 02/12/25

Most Recent Stories

More News
CytomX Therapeutics to Present at Upcoming February Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 5.43 (-2.34%)
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CTMX : 5.43 (-2.34%)
CRDF : 1.5800 (-1.25%)
CytomX Therapeutics Announces Business Update and Company Milestones for 2026

- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal...

CTMX : 5.43 (-2.34%)
CytomX Therapeutics to Present at Upcoming December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 5.43 (-2.34%)
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean...

CTMX : 5.43 (-2.34%)
CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics: Q3 Earnings Snapshot

CTMX : 5.43 (-2.34%)
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC...

CTMX : 5.43 (-2.34%)
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

- CX-801 (PROBODY ® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism...

CTMX : 5.43 (-2.34%)
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 5.43 (-2.34%)
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 5.43 (-2.34%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 5.75
2nd Resistance Point 5.65
1st Resistance Point 5.54
Last Price 5.43
1st Support Level 5.33
2nd Support Level 5.24
3rd Support Level 5.13

See More

52-Week High 6.35
Last Price 5.43
Fibonacci 61.8% 4.08
Fibonacci 50% 3.38
Fibonacci 38.2% 2.67
52-Week Low 0.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar